Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
13 11 2019
Historique:
received: 26 11 2018
revised: 10 07 2019
accepted: 21 10 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 5 9 2020
Statut: ppublish

Résumé

The presence of B lymphocyte-associated oligoclonal immunoglobulins in the cerebrospinal fluid is a classic hallmark of multiple sclerosis (MS). The clinical efficacy of anti-CD20 therapies supports a major role for B lymphocytes in MS development. Although activated oligoclonal populations of pathogenic B lymphocytes are able to traffic between the peripheral circulation and the central nervous system (CNS) in patients with MS, molecular players involved in this migration have not yet been elucidated. In this study, we demonstrated that activated leukocyte cell adhesion molecule (ALCAM/CD166) identifies subsets of proinflammatory B lymphocytes and drives their transmigration across different CNS barriers in mouse and human. We also showcased that blocking ALCAM alleviated disease severity in animals affected by a B cell-dependent form of experimental autoimmune encephalomyelitis. Last, we determined that the proportion of ALCAM

Identifiants

pubmed: 31723036
pii: 11/518/eaaw0475
doi: 10.1126/scitranslmed.aaw0475
pii:
doi:

Substances chimiques

Activated-Leukocyte Cell Adhesion Molecule 0
Myelin-Oligodendrocyte Glycoprotein 0
Recombinant Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Laure Michel (L)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Camille Grasmuck (C)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Marc Charabati (M)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Marc-André Lécuyer (MA)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Stephanie Zandee (S)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Tessa Dhaeze (T)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Jorge I Alvarez (JI)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Rui Li (R)

Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Sandra Larouche (S)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Lyne Bourbonnière (L)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Robert Moumdjian (R)

Division of Neurosurgery, CHUM, Montréal, QC H2X 3E4, Canada.

Alain Bouthillier (A)

Division of Neurosurgery, CHUM, Montréal, QC H2X 3E4, Canada.

Boaz Lahav (B)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Pierre Duquette (P)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Amit Bar-Or (A)

Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Jennifer L Gommerman (JL)

Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Evelyn Peelen (E)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Alexandre Prat (A)

Department of Neuroscience, Faculty of Medicine, Université de Montréal, Montréal, QC Canada. a.prat@umontreal.ca.
Neuroimmunology Unit, Centre de recherche du CHUM (CRCHUM), Montréal, QC H2X 0A9, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH